{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:19Z","timestamp":1792176379771,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ili Kazakh Autonomous Prefecture Science and Technology Program Project","award":["YJC2024A15"],"award-info":[{"award-number":["YJC2024A15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12944-y","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:42Z","timestamp":1792173342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ITF2357 exerts anti\u2011tumor activity in colorectal cancer via the miR\u20111938\/ADAM12 axis"],"prefix":"10.1007","volume":"53","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zulihumaer","family":"Yakupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusupujiang","family":"Maimaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baligen","family":"Salikebai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairepati","family":"Mahemuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeerbulati","family":"Daoken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6447-844X","authenticated-orcid":false,"given":"Zeyidan","family":"Jiapaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"12944_CR1","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.3322\/caac.70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung H et al (2026) Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin 76:e70090. https:\/\/doi.org\/10.3322\/caac.70090","journal-title":"CA Cancer J Clin"},{"key":"12944_CR2","doi-asserted-by":"publisher","DOI":"10.2174\/0115734129329774240829073320","author":"S Khanra","year":"2024","unstructured":"Khanra S et al (2024) Development and Validation of an RP-UFLC Method for the Estimation of Oxaliplatin Drug for the Preparation of Oxaliplatin Nanoparticles. Curr Pharm Anal. https:\/\/doi.org\/10.2174\/0115734129329774240829073320","journal-title":"Curr Pharm Anal"},{"key":"12944_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232336447241010094744","author":"M Suleman","year":"2024","unstructured":"Suleman M et al (2024) Probing the Depths of Molecular Complexity: STAT3 as a Key Architect in Colorectal Cancer Pathogenesis. Curr Gene Ther. https:\/\/doi.org\/10.2174\/0115665232336447241010094744","journal-title":"Curr Gene Ther"},{"key":"12944_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41575-019-0230-y","volume":"17","author":"G Jung","year":"2020","unstructured":"Jung G, Hern\u00e1ndez-Ill\u00e1n E, Moreira L, Balaguer F, Goel A (2020) Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol 17:111\u2013130. https:\/\/doi.org\/10.1038\/s41575-019-0230-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"12944_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mam.2016.10.001","volume":"54","author":"S O\u2019Reilly","year":"2017","unstructured":"O\u2019Reilly S (2017) Epigenetics in fibrosis. Mol Aspects Med 54:89\u2013102. https:\/\/doi.org\/10.1016\/j.mam.2016.10.001","journal-title":"Mol Aspects Med"},{"key":"12944_CR6","doi-asserted-by":"publisher","first-page":"e13657","DOI":"10.1111\/acel.13657","volume":"21","author":"Z Jiapaer","year":"2022","unstructured":"Jiapaer Z et al (2022) Regulation and roles of RNA modifications in aging-related diseases. Aging Cell 21:e13657. https:\/\/doi.org\/10.1111\/acel.13657","journal-title":"Aging Cell"},{"key":"12944_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/14737159.2016.1135057","volume":"16","author":"F Ma","year":"2016","unstructured":"Ma F, Zhang CY (2016) Histone modifying enzymes: novel disease biomarkers and assay development. Expert Rev Mol Diagn 16:297\u2013306. https:\/\/doi.org\/10.1586\/14737159.2016.1135057","journal-title":"Expert Rev Mol Diagn"},{"key":"12944_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","volume":"39","author":"R Chen","year":"2020","unstructured":"Chen R et al (2020) The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res 39:138. https:\/\/doi.org\/10.1186\/s13046-020-01643-6","journal-title":"J Exp Clin Cancer Res"},{"key":"12944_CR9","doi-asserted-by":"publisher","first-page":"116257","DOI":"10.1016\/j.bcp.2024.116257","volume":"225","author":"R Jenke","year":"2024","unstructured":"Jenke R et al (2024) HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer. Biochem Pharmacol 225:116257. https:\/\/doi.org\/10.1016\/j.bcp.2024.116257","journal-title":"Biochem Pharmacol"},{"key":"12944_CR10","doi-asserted-by":"publisher","first-page":"109297","DOI":"10.1016\/j.apradiso.2020.109297","volume":"164","author":"M Perona","year":"2020","unstructured":"Perona M et al (2020) Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC). Appl Radiat Isot 164:109297. https:\/\/doi.org\/10.1016\/j.apradiso.2020.109297","journal-title":"Appl Radiat Isot"},{"key":"12944_CR11","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.7150\/thno.48314","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T et al (2021) The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer. Theranostics 11:2058\u20132076. https:\/\/doi.org\/10.7150\/thno.48314","journal-title":"Theranostics"},{"key":"12944_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","volume":"17","author":"A Furlan","year":"2011","unstructured":"Furlan A et al (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 17:353\u2013362. https:\/\/doi.org\/10.2119\/molmed.2011.00020","journal-title":"Mol Med"},{"key":"12944_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.onc.1210820","volume":"27","author":"V Barbetti","year":"2008","unstructured":"Barbetti V et al (2008) Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1\/ETO-positive cells. Oncogene 27:1767\u20131778. https:\/\/doi.org\/10.1038\/sj.onc.1210820","journal-title":"Oncogene"},{"key":"12944_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-023-03973-3","volume":"21","author":"J Cui","year":"2023","unstructured":"Cui J et al (2023) HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2\/miR-130a-3p-dependent mechanism. J Transl Med 21:125. https:\/\/doi.org\/10.1186\/s12967-023-03973-3","journal-title":"J Transl Med"},{"key":"12944_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"F Leoni","year":"2005","unstructured":"Leoni F et al (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11:1\u201315. https:\/\/doi.org\/10.2119\/2006-00005.Dinarello","journal-title":"Mol Med"},{"key":"12944_CR16","doi-asserted-by":"publisher","first-page":"860661","DOI":"10.3389\/fimmu.2022.860661","volume":"13","author":"J Gu","year":"2022","unstructured":"Gu J, Xu H, Chen Y, Li N, Hou X (2022) MiR-223 as a Regulator and Therapeutic Target in Liver Diseases. Front Immunol 13:860661. https:\/\/doi.org\/10.3389\/fimmu.2022.860661","journal-title":"Front Immunol"},{"key":"12944_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1871530320666200825184924","volume":"21","author":"SS Sampath","year":"2021","unstructured":"Sampath SS, Venkatabalasubramanian S, Ramalingam S (2021) Role of MicroRNAs in the Progression and Metastasis of Colon Cancer. Endocr Metab Immune Disord Drug Targets 21:35\u201346. https:\/\/doi.org\/10.2174\/1871530320666200825184924","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"12944_CR18","doi-asserted-by":"publisher","first-page":"e21895","DOI":"10.1097\/md.0000000000021895","volume":"99","author":"C Br\u00eenzan","year":"2020","unstructured":"Br\u00eenzan C, A\u015fchie M, Cozaru G, Dumitru E, Mitroi A (2020) The diagnostic value of miR-92a, -143, and \u2013\u2009145 expression levels in patients with colorectal adenocarcinoma from Romania. Med (Baltim) 99:e21895. https:\/\/doi.org\/10.1097\/md.0000000000021895","journal-title":"Med (Baltim)"},{"key":"12944_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/jcp.25801","volume":"233","author":"A Moridikia","year":"2018","unstructured":"Moridikia A, Mirzaei H, Sahebkar A, Salimian J, MicroRNAs (2018) Potential candidates for diagnosis and treatment of colorectal cancer. J Cell Physiol 233:901\u2013913. https:\/\/doi.org\/10.1002\/jcp.25801","journal-title":"J Cell Physiol"},{"key":"12944_CR20","doi-asserted-by":"publisher","first-page":"823620","DOI":"10.1155\/2015\/823620","volume":"2015","author":"J Wang","year":"2015","unstructured":"Wang J, Du Y, Liu X, Cho WC, Yang Y (2015) MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. Biomed Res Int 2015:823620. https:\/\/doi.org\/10.1155\/2015\/823620","journal-title":"Biomed Res Int"},{"key":"12944_CR21","doi-asserted-by":"publisher","DOI":"10.2174\/0109298665248028231122064831","author":"Z Xu","year":"2023","unstructured":"Xu Z, Yu Y, Ni H, Sun W, Kuang Y (2023) LINC01836 Promotes Colorectal Cancer Progression and Functions as ceRNA to Target SLC17A9 by Sponging miR-1226-3p. Protein Pept Lett. https:\/\/doi.org\/10.2174\/0109298665248028231122064831","journal-title":"Protein Pept Lett"},{"key":"12944_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2174\/1874467216666230210091839","volume":"16","author":"S Kiran","year":"2023","unstructured":"Kiran S et al (2023) Restoration of Altered Oncogenic and Tumor Suppressor microRNA Expression in Breast Cancer and Colorectal Cancer Cell using Epicatechin. Curr Mol Pharmacol 16:915\u2013926. https:\/\/doi.org\/10.2174\/1874467216666230210091839","journal-title":"Curr Mol Pharmacol"},{"key":"12944_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.biopha.2016.09.099","volume":"84","author":"A Mohammadi","year":"2016","unstructured":"Mohammadi A, Mansoori B, Baradaran B (2016) The role of microRNAs in colorectal cancer. Biomed Pharmacother 84:705\u2013713. https:\/\/doi.org\/10.1016\/j.biopha.2016.09.099","journal-title":"Biomed Pharmacother"},{"key":"12944_CR24","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.2147\/ott.S219421","volume":"12","author":"W Jin","year":"2019","unstructured":"Jin W, Shi J, Liu M (2019) Overexpression of miR-671-5p indicates a poor prognosis in colon cancer and accelerates proliferation, migration, and invasion of colon cancer cells. Onco Targets Ther 12:6865\u20136873. https:\/\/doi.org\/10.2147\/ott.S219421","journal-title":"Onco Targets Ther"},{"key":"12944_CR25","doi-asserted-by":"publisher","first-page":"20841","DOI":"10.1038\/srep20841","volume":"6","author":"RR Lim","year":"2016","unstructured":"Lim RR et al (2016) ITF2357 transactivates Id3 and regulate TGF\u03b2\/BMP7 signaling pathways to attenuate corneal fibrosis. Sci Rep 6:20841. https:\/\/doi.org\/10.1038\/srep20841","journal-title":"Sci Rep"},{"key":"12944_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4161\/epi.3.1.5736","volume":"3","author":"JM Mariadason","year":"2008","unstructured":"Mariadason JM (2008) HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28\u201337. https:\/\/doi.org\/10.4161\/epi.3.1.5736","journal-title":"Epigenetics"},{"key":"12944_CR27","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1096\/fj.201801390R","volume":"33","author":"Y Hu","year":"2019","unstructured":"Hu Y et al (2019) RAR\u03b2 acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells. Faseb j 33:2314\u20132326. https:\/\/doi.org\/10.1096\/fj.201801390R","journal-title":"Faseb j"},{"key":"12944_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.apsb.2021.07.003","volume":"12","author":"X Sun","year":"2022","unstructured":"Sun X et al (2022) Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy. Acta Pharm Sin B 12:838\u2013852. https:\/\/doi.org\/10.1016\/j.apsb.2021.07.003","journal-title":"Acta Pharm Sin B"},{"key":"12944_CR29","doi-asserted-by":"publisher","first-page":"15336","DOI":"10.18632\/aging.203091","volume":"13","author":"Y Shi","year":"2021","unstructured":"Shi Y et al (2021) Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma. Aging 13:15336\u201315352. https:\/\/doi.org\/10.18632\/aging.203091","journal-title":"Aging"},{"key":"12944_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-019-1080-8","volume":"38","author":"L He","year":"2019","unstructured":"He L et al (2019) Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. J Exp Clin Cancer Res 38:84. https:\/\/doi.org\/10.1186\/s13046-019-1080-8","journal-title":"J Exp Clin Cancer Res"},{"key":"12944_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","volume":"150","author":"A Rambaldi","year":"2010","unstructured":"Rambaldi A et al (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150:446\u2013455. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08266.x","journal-title":"Br J Haematol"},{"key":"12944_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00432-018-2800-8","volume":"145","author":"F Marampon","year":"2019","unstructured":"Marampon F et al (2019) Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. J Cancer Res Clin Oncol 145:393\u2013409. https:\/\/doi.org\/10.1007\/s00432-018-2800-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"12944_CR33","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.3892\/or.2017.5605","volume":"37","author":"Y Wang","year":"2017","unstructured":"Wang Y et al (2017) MicroRNA-1299 is a negative regulator of STAT3 in colon cancer. Oncol Rep 37:3227\u20133234. https:\/\/doi.org\/10.3892\/or.2017.5605","journal-title":"Oncol Rep"},{"key":"12944_CR34","doi-asserted-by":"publisher","unstructured":"Wang H (2020) MicroRNAs and Apoptosis in Colorectal Cancer. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21155353","DOI":"10.3390\/ijms21155353"},{"key":"12944_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ceb.2020.08.015","volume":"67","author":"H Galagali","year":"2020","unstructured":"Galagali H, Kim JK (2020) The multifaceted roles of microRNAs in differentiation. Curr Opin Cell Biol 67:118\u2013140. https:\/\/doi.org\/10.1016\/j.ceb.2020.08.015","journal-title":"Curr Opin Cell Biol"},{"key":"12944_CR36","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3892\/ol.2018.8905","volume":"16","author":"X Han","year":"2018","unstructured":"Han X, Zheng J, Wang Y, Gao Z (2018) miRNA-29a inhibits colon cancer growth by regulation of the PTEN\/Akt\/GSK3\u03b2 and Wnt\/\u03b2-catenin signaling pathways. Oncol Lett 16:2638\u20132644. https:\/\/doi.org\/10.3892\/ol.2018.8905","journal-title":"Oncol Lett"},{"key":"12944_CR37","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/0008-5472.Can-17-3003","volume":"78","author":"P Ullmann","year":"2018","unstructured":"Ullmann P et al (2018) The miR-371\u223c373 Cluster Represses Colon Cancer Initiation and Metastatic Colonization by Inhibiting the TGFBR2\/ID1 Signaling Axis. Cancer Res 78:3793\u20133808. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-3003","journal-title":"Cancer Res"},{"key":"12944_CR38","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1158\/0008-5472.Can-17-1767","volume":"77","author":"AR Lulla","year":"2017","unstructured":"Lulla AR et al (2017) miR-6883 Family miRNAs Target CDK4\/6 to Induce G(1) Phase Cell-Cycle Arrest in Colon Cancer Cells. Cancer Res 77:6902\u20136913. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1767","journal-title":"Cancer Res"},{"key":"12944_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13073-025-01530-9","volume":"17","author":"AH de Sande","year":"2025","unstructured":"de Sande AH et al (2025) MicroRNA gene dynamics in immune cell subpopulations during aging and atherosclerosis disease development at single-cell resolution. Genome Med 17:112. https:\/\/doi.org\/10.1186\/s13073-025-01530-9","journal-title":"Genome Med"},{"key":"12944_CR40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3892\/ijo.2020.5007","volume":"56","author":"L Wang","year":"2020","unstructured":"Wang L et al (2020) ADAM12 silencing promotes cellular apoptosis by activating autophagy in choriocarcinoma cells. Int J Oncol 56:1162\u20131174. https:\/\/doi.org\/10.3892\/ijo.2020.5007","journal-title":"Int J Oncol"},{"key":"12944_CR41","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1038\/s41598-022-10608-y","volume":"12","author":"S Du","year":"2022","unstructured":"Du S et al (2022) ADAM12 is an independent predictor of poor prognosis in liver cancer. Sci Rep 12:6634. https:\/\/doi.org\/10.1038\/s41598-022-10608-y","journal-title":"Sci Rep"},{"key":"12944_CR42","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/1541-7786.Mcr-17-0188","volume":"15","author":"R Roy","year":"2017","unstructured":"Roy R, Dagher A, Butterfield C, Moses MA (2017) ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Mol Cancer Res 15:1608\u20131622. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-17-0188","journal-title":"Mol Cancer Res"},{"key":"12944_CR43","doi-asserted-by":"publisher","first-page":"729230","DOI":"10.3389\/fonc.2021.729230","volume":"11","author":"Z Huang","year":"2021","unstructured":"Huang Z et al (2021) Upregulation of ADAM12 Is Associated With a Poor Survival and Immune Cell Infiltration in Colon Adenocarcinoma. Front Oncol 11:729230. https:\/\/doi.org\/10.3389\/fonc.2021.729230","journal-title":"Front Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12944-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12944-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:55:43Z","timestamp":1792173343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12944-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12944"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12944-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ting Wang, Lingying Zhang, Zulihumaer Yakupu, Xiaojing Shi, Yusupujiang Maimaiti, Baligen Salikebai, Mairepati Mahemuti, Hongbing Xiao, Yeerbulati Daoken, Zhili Wang, Baoming Zhang, and Zeyidan Jiapaer declare that they have no financial or non-financial competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were approved by the Animal Ethics Committee of the College of Life Sciences and Technology, Xinjiang University (Approval No. XJUAE-2025-004) and conducted in accordance with institutional guidelines for animal use and management.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1753"}}